Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96


Chemotoxicity recurrence in older patients: Risk factors and effectiveness of preventive strategies-a prospective study.

Extermann M, Reich RR, Sehovic M.

Cancer. 2015 Sep 1;121(17):2984-92. doi: 10.1002/cncr.29423. Epub 2015 May 29.


Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score.

Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, Levine RM, Lubiner ET, Reyes P, Schreiber FJ 3rd, Balducci L.

Cancer. 2012 Jul 1;118(13):3377-86. doi: 10.1002/cncr.26646. Epub 2011 Nov 9.


Can older cancer patients tolerate chemotherapy? A prospective pilot study.

Chen H, Cantor A, Meyer J, Beth Corcoran M, Grendys E, Cavanaugh D, Antonek S, Camarata A, Haley W, Balducci L, Extermann M.

Cancer. 2003 Feb 15;97(4):1107-14.


Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial.

Brain EG, Mertens C, Girre V, Rousseau F, Blot E, Abadie S, Uwer L, Bourbouloux E, Van Praagh-Doreau I, Mourey L, Kirscher S, Laguerre B, Fourme E, Luneau S, Genève J, Debled M.

Crit Rev Oncol Hematol. 2011 Oct;80(1):160-70. doi: 10.1016/j.critrevonc.2010.10.003. Epub 2010 Oct 28.


Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer.

Wildes TM, Ruwe AP, Fournier C, Gao F, Carson KR, Piccirillo JF, Tan B, Colditz GA.

J Geriatr Oncol. 2013 Jul;4(3):227-34.


Clinical Impact of Chemotherapy-Related Adverse Events in Patients with Metastatic Breast Cancer in an Integrated Health Care System.

Rashid N, Koh HA, Baca HC, Li Z, Malecha S, Abidoye O, Masaquel A.

J Manag Care Spec Pharm. 2015 Oct;21(10):863-71.


Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group.

Feliu J, López Gómez L, Madroñal C, Espinosa E, Espinosa J, Girón CG, Martínez B, Castro J, De la Gándara I, Barón MG.

Cancer. 1999 Oct 15;86(8):1463-9.


Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.

Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Johnson S, Ozols RF.

Semin Oncol. 1995 Aug;22(4 Suppl 9):18-29.


Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.

Pentheroudakis G, Fountzilas G, Kalofonos HP, Golfinopoulos V, Aravantinos G, Bafaloukos D, Papakostas P, Pectasides D, Christodoulou C, Syrigos K, Economopoulos T, Pavlidis N; Hellenic Cooperative Oncology Group.

Crit Rev Oncol Hematol. 2008 Jun;66(3):237-47. doi: 10.1016/j.critrevonc.2007.12.003. Epub 2008 Feb 1.


Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy.

Shayne M, Culakova E, Wolff D, Poniewierski MS, Dale DC, Crawford J, Lyman GH.

Cancer. 2009 Nov 15;115(22):5319-28. doi: 10.1002/cncr.24560.


Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.

Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, Gridelli C, Gebbia V, Ciardiello F, De Placido S, Ceribelli A, Favaretto AG, de Matteis A, Feld R, Butts C, Bryce J, Signoriello S, Morabito A, Rocco G, Perrone F.

J Clin Oncol. 2015 Mar 10;33(8):910-5. doi: 10.1200/JCO.2014.57.9334. Epub 2015 Jan 26.


Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer.

Tibaldi C, Bernardini I, Chella A, Russo F, Vasile E, Malventi M, Falcone A.

Clin Lung Cancer. 2006 May;7(6):401-5.


Risk Factors for Chemotherapy-Related Toxicity and Adverse Events in Elderly Thai Cancer Patients: A Prospective Study.

Phaibulvatanapong E, Srinonprasert V, Ithimakin S.

Oncology. 2018;94(3):149-160. doi: 10.1159/000485078. Epub 2017 Dec 7.


Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.

Weycker D, Malin J, Kim J, Barron R, Edelsberg J, Kartashov A, Oster G.

Clin Ther. 2009 May;31(5):1069-81. doi: 10.1016/j.clinthera.2009.05.019.


Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.

Shayne M, Culakova E, Poniewierski MS, Wolff D, Dale DC, Crawford J, Lyman GH.

Cancer. 2007 Oct 1;110(7):1611-20.


Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma .

Sweeney CJ, Zhu J, Sandler AB, Schiller J, Belani CP, Langer C, Krook J, Harrington D, Johnson DH.

Cancer. 2001 Nov 15;92(10):2639-47.


A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).

von Minckwitz G, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, Hackmann J, Möbus V, Marmé F, Potenberg J, Stickeler E, Simon E, Thomssen C, Huober J, Denkert C, Alfer J, Jackisch C, Nekljudova V, Burchardi N, Loibl S; German Breast Group Investigators.

Cancer. 2015 Oct 15;121(20):3639-48. doi: 10.1002/cncr.29506. Epub 2015 Jun 25.


Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice.

Crawford J, Dale DC, Kuderer NM, Culakova E, Poniewierski MS, Wolff D, Lyman GH.

J Natl Compr Canc Netw. 2008 Feb;6(2):109-18.


Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.

Hamaker ME, Seynaeve C, Wymenga AN, van Tinteren H, Nortier JW, Maartense E, de Graaf H, de Jongh FE, Braun JJ, Los M, Schrama JG, van Leeuwen-Stok AE, de Groot SM, Smorenburg CH.

Breast. 2014 Feb;23(1):81-7. doi: 10.1016/j.breast.2013.11.004. Epub 2013 Dec 5.


Supplemental Content

Support Center